Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1904 in advanced pancreatic cancer
NCT04928625Phase 1Unknown
- Sponsor
- Hengrui Therapeutics
- Start
- Aug 2021
- Primary completion
- Jun 2023
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of garetatug rezetecan in pancreatic cancer (PC), sponsored by Hengrui Therapeutics. Primary endpoints: Dose-limiting toxicity up to 2 months, Maximum tolerated dose up to 2 months and 1 more. Status: unknown.
02
Drugs
garetatug rezetecan
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04928625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04928625.